Search the Newsreel

bioAffinity Technologies to Add Mexican Patent to its CyPath Lung Technology IP

bioAffinity Technologies Inc. has received notification of patent allowance in Mexico for its CyPath Lung technology, further strengthening its global intellectual property portfolio. This patent protects the use of flow cytometry and specific labeling methods for detecting lung cancer cells in sputum, expanding on …

Form 8K bioAffinity Technologies Inc For: 7 August By Investing.com

The article reports that bioAffinity Technologies Inc. filed a Form 8K on August 7th. It briefly mentions the company's stock symbol BIAF and includes general financial market data such as indices, commodities, and shares. The content is primarily a placeholder or boilerplate for financial …

bioAffinity Technologies, Inc. Q2 2026: Revenue $1.51M, EPS $(0.64) — 10-Q Summary

bioAffinity Technologies, Inc. (BIAF) reported its Q2 2026 financial results, with revenue increasing by 19% year-over-year to $1.51M. The company narrowed its net loss to $3.37M, and diluted loss per share improved to $(0.64). Key business highlights include significant growth in CyPath® Lung revenue …

BioAffinity Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

BioAffinity Technologies, Inc. has released its earnings results for the second quarter and six months ending June 30, 2026. For the second quarter, the company saw an increase in sales to USD 1.51 million compared to USD 1.27 million a year ago, while reducing …

Press Release: BioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath(R) Lung

BioAffinity Technologies announced its financial results for the second quarter of 2026, highlighting strong commercial growth for its CyPath® Lung diagnostic. The company reported a significant increase in test volumes and revenue compared to the previous year, driven by expanding insurance coverage and successful …

bioAffinity Technologies earnings beat by $1.46, revenue fell short of estimates

bioAffinity Technologies (NASDAQ: BIAF) reported a second-quarter EPS of $-0.640, significantly beating the analyst estimate of $-2.100 by $1.46. However, the company's revenue for the quarter was $1.5M, falling short of the consensus estimate of $1.7M. The stock has experienced a significant decline over …

bioAffinity Technologies reports Q2 2026 revenue $1.51M, net loss $3.37M, cash $2.43M

bioAffinity Technologies reported its Q2 2026 financial results, showing revenue of $1.51 million, an increase from $1.27 million in Q2 2025, and a net loss of $3.37 million, an improvement from $4.06 million in Q2 2025. The company's cash and cash equivalents decreased to …

BIAF: Q2 2026 saw 216% CyPath Lung test growth and 19% revenue increase, with improved net loss

BioAffinity Technologies (BIAF) reported significant growth in Q2 2026, with CyPath Lung test volume increasing by 216% and revenue by 19%. This growth was attributed to accelerated physician adoption and expanded clinical trials. Despite increased operating expenses due to commercialization efforts, the company improved …

Enterprise value to EBIT forward of bioAffinity Technologies, Inc. – NASDAQ:BIAF

This article provides financial data for bioAffinity Technologies, Inc. (NASDAQ: BIAF), specifically its Enterprise Value to EBIT forward. The content is presented through TradingView, offering an overview of financials, news, and community sentiment for the company. The data is supplied by ICE Data Services …

bioAffinity Technologies Faces Nasdaq Delisting Risk After Notice

bioAffinity Technologies (BIAF) has received a delisting notice from Nasdaq because its stock failed to maintain the minimum $1.00 bid price for 30 consecutive business days. The company is ineligible for the standard compliance period due to a reverse stock split in the previous …

bioAffinity Technologies Received Notice of Delisting

bioAffinity Technologies (BIAF) has received a delisting notice from Nasdaq because its stock failed to maintain the minimum $1.00 bid price for 30 consecutive business days. The company is ineligible for the standard compliance period due to a reverse stock split in the previous …

Price to earnings forward of bioAffinity Technologies, Inc. – NASDAQ:BIAF

This article provides financial information for bioAffinity Technologies, Inc. (NASDAQ: BIAF) on TradingView. It specifically highlights the company's "Price to earnings forward" metric. The content emphasizes that the data is compiled by humans and sourced from ICE Data Services and FactSet.

BIAF|bioAffinity Technologies Inc|Price:0.593|Chg%:-0.035

bioAffinity Technologies Inc. (BIAF) currently trades at $0.644, up 10.15% at market close on July 30th, 2026, with a market cap of $2.90M. The company, which specializes in noninvasive diagnostics for early-stage lung cancer, has shown strong revenue and profit growth but its stock …

Press Release issued by bioAffinity Technologies, Inc., dated July 27, 2026 - SEC.gov

bioAffinity Technologies announced the publication of a new clinical framework white paper, "Lung Nodules, Lung Microenvironment, Predictive Models and Clinician Risk Stratification Using CyPath ® Lung Testing for Early Diagnosis of Lung Cancer," authored by its Chief Medical Officer. This framework integrates CyPath ® …

bioAffinity Technologies, Inc. Revenue Breakdown – BOATS:BIAFW

bioAffinity Technologies, Inc. (BIAFW) generated $6.16 million USD in revenue last year, primarily from its Laboratory Services segment, which also contributed the most in the previous year at $9.35 million USD. The majority of this revenue, $6.16 million USD, originated from the United States, …

bioAffinity, Pictor Collaborate on Asthma and COPD Tests

bioAffinity Technologies and Pictor, Inc. have announced a collaboration to develop and commercialize diagnostic tests for asthma and COPD. These tests will combine flow cytometry and targeted proteomic analysis of sputum samples to identify specific inflammatory pathways, aiming to advance precision medicine for chronic …

bioAffinity Technologies publishes clinical framework to integrate CyPath® Lung into nodule evaluation

bioAffinity Technologies has published a clinical review outlining a practical framework to integrate CyPath® Lung into pulmonary nodule evaluation and cancer surveillance. The white paper, presented by CMO Dr. Gordon H. Downie, targets primary care, interventional pulmonology, and oncology practices to improve risk stratification. …

bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung

bioAffinity Technologies has published a new clinical framework in a white paper titled "Lung Nodules, Lung Microenvironment, Predictive Models and Clinician Risk Stratification Using CyPath® Lung Testing for Early Diagnosis of Lung Cancer." This framework outlines how CyPath® Lung, a noninvasive test, can be …

BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?

This article compares two cancer diagnostics companies, bioAffinity Technologies (BIAF) and Biodesix (BDSX), to determine which is a better investment. While BIAF focuses on early-stage lung cancer detection with its CyPath Lung test and has strong growth potential, it is in an earlier commercial …

bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity's Diagnostics for Asthma and COPD | Newswise

bioAffinity Technologies and Pictor®, Inc. have partnered to develop and commercialize bioAffinity's next-generation diagnostic tests for asthma and chronic obstructive pulmonary disease (COPD). This collaboration aims to enhance the throughput and reduce the costs of personalized testing by integrating bioAffinity's flow cytometry expertise with …

bioAffinity Technologies Inc (BIAF) Cash Flow Statement

This article presents the quarterly and annual cash flow statements for bioAffinity Technologies Inc (BIAF), detailing operating, investing, and financing cash flows. It includes financial figures for various quarters and years, along with definitions and FAQs about different types of cash flow and their …

bioAffinity Technologies, Inc. (BIAF) Stock Price, News, Quote & History

This article provides detailed financial information and an overview of bioAffinity Technologies, Inc. (BIAF). It covers the company's stock performance, key financial metrics, news, and its work in developing non-invasive diagnostic tests for early-stage lung cancer and other lung diseases. The company utilizes flow …

bioAffinity Technologies partners with Pictor to develop high-throughput asthma and COPD diagnostics

bioAffinity Technologies announced a collaboration with Pictor to develop high-throughput diagnostics for asthma and COPD, integrating bioAffinity's flow cytometry sputum platform with Pictor's proteomic analysis. This partnership aims to enhance lab throughput, reduce costs, and offer scalable diagnostic testing. bioAffinity will retain IP rights …

Certain Common Stock of bioAffinity Technologies, Inc. are subject to a Lock-Up Agreement Ending on 19-JUL-2026.

Certain Common Stock of bioAffinity Technologies, Inc. are subject to a lock-up agreement that concludes on July 19, 2026. This agreement restricts officers and directors from selling or otherwise disposing of their common stock for 31 days, from June 18, 2026, to July 19, …

CyPath Lung sales top prior quarter as bioAffinity sees 200% growth

BioAffinity Technologies Projects Strong Growth Amid Market Fluctuations

BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung

BIAF Stock Gains As CyPath Sales Surge 146% In Q1

bioAffinity Technologies 10-K: Revenue $6.16M, EPS $(8.66)

bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung

bioAffinity Technologies (BIAF) Earnings Date and Reports 2026 $BIAF

bioAffinity Technologies, Inc. (BIAF)